trial

A Study to Evaluate the Efficacy and Safety of KarXT in Acutely Psychotic Japanese Adult Participants With Schizophrenia

NCTId NCT06882785
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 3 · Recruiting
Enrollment 250 (estimated)
Sponsored by Bristol-Myers
Primary completion 2028-09-23
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 3
Status
Recruiting
Enrollment
250 (estimated)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Double
Start
2025-06-10
Primary completion
2028-09-23
Eligibility
ALL · 18 Years · 65 Years

Interventions & indications

Drugs
Xanomeline-trospium (Cobenfy)

Sponsors

Bristol-MyersLead Sponsor

Sites

56 total
Kōnan, JapanNagoya, JapanToyoake, JapanToyoake, JapanIchikawa, JapanMIdori-ku, Chiba-shi, JapanIizuka, JapanKitakyushu, JapanOmuta, JapanAizu-Wakamatsu, JapanToki, JapanKure, Japan

Linked catalysts

1
A Study to Evaluate the Efficacy and Safety of KarXT in Acutely Psychotic Japane — primary completion2028-09-23

Facts & assertions

4 sourced
Enrollment
250
Phase
PHASE3
Primary Completion Date
2028-09-23
Status
RECRUITING
relationships
The graph out of here
drug
Xanomeline-trospium (Cobenfy)
drug
lead_sponsor
Bristol-Myers
company
indication
Schizophrenia
indication
Schizophrenia
indication